Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (431-440 of 768) with videos related to

Pageof 77
Sort By:
Blood|December 12, 2019
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?Stefan O Ciurea, Piyanuch Kongtim, Ankur Varma, et al.
Leukemia|July 6, 2007
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantationB Oran, S Giralt, D Couriel, et al.
Blood|June 21, 2008
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasmsConstantine S Tam, Roberto M Nussenzveig, Uday Popat, et al.
American Journal of Hematology|April 23, 2009
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphomaChitra Hosing, Rima M Saliba, Sheena Ahlawat, et al.
Bone Marrow Transplantation|October 21, 2000
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's diseaseP Anderlini, S Giralt, B Andersson, et al.
Blood Advances|June 21, 2019
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioningKoen van Besien, Andrew Artz, Richard E Champlin, et al.
Blood|April 10, 2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Daniel Couriel, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 29, 2017
Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation OutcomesGabriela Rondón, Rima M Saliba, Julianne Chen, et al.
American Journal of Hematology|July 1, 2020
Haploidentical transplants for patients with graft failure after the first allograftPiyanuch Kongtim, Maria Bittencourt, Samer A Srour, et al.
Journal of Cancer|October 18, 2012
Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell TransplantationMichal Mego, Hui Gao, Bang-Ning Lee, et al.
Pageof 77

Showing results (431-440 of 768) with videos related to

Sort By:
Pageof 77
Blood|December 12, 2019
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?Stefan O Ciurea, Piyanuch Kongtim, Ankur Varma, et al.
Leukemia|July 6, 2007
Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantationB Oran, S Giralt, D Couriel, et al.
Blood|June 21, 2008
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasmsConstantine S Tam, Roberto M Nussenzveig, Uday Popat, et al.
American Journal of Hematology|April 23, 2009
Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphomaChitra Hosing, Rima M Saliba, Sheena Ahlawat, et al.
Bone Marrow Transplantation|October 21, 2000
Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's diseaseP Anderlini, S Giralt, B Andersson, et al.
Blood Advances|June 21, 2019
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioningKoen van Besien, Andrew Artz, Richard E Champlin, et al.
Blood|April 10, 2004
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDSMarcos de Lima, Daniel Couriel, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 29, 2017
Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation OutcomesGabriela Rondón, Rima M Saliba, Julianne Chen, et al.
American Journal of Hematology|July 1, 2020
Haploidentical transplants for patients with graft failure after the first allograftPiyanuch Kongtim, Maria Bittencourt, Samer A Srour, et al.
Journal of Cancer|October 18, 2012
Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell TransplantationMichal Mego, Hui Gao, Bang-Ning Lee, et al.
Pageof 77